Biotechnology company 🇺🇸, United States
Superluminal develops investigational medicines, including an obesity program targeting MC4R. Its Series B financing supports that program and further drug discovery, with Eli Lilly among the investors. This profile follows the company’s funding and development activity, including potential use of its treatments alongside GLP-1 therapies.
Market cap not yet added.
Last 12 months
Last 12 months
Investors led by BVF Partners are providing Superluminal with $60 million to advance an experimental obesity treatment. Lilly is participating as an investor in this funding round.
Grow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
